Eyepoint Pharmaceuticals (EYPT) Competitors $13.41 +0.06 (+0.45%) Closing price 04:00 PM EasternExtended Trading$13.25 -0.16 (-1.19%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EYPT vs. CAMT, TXG, ALNT, AEHR, TRNS, CTKB, LAB, SENS, FEIM, and QSIShould you be buying Eyepoint Pharmaceuticals stock or one of its competitors? The main competitors of Eyepoint Pharmaceuticals include Camtek (CAMT), 10x Genomics (TXG), Allient (ALNT), Aehr Test Systems (AEHR), Transcat (TRNS), Cytek Biosciences (CTKB), Standard BioTools (LAB), Senseonics (SENS), Frequency Electronics (FEIM), and Quantum-Si (QSI). These companies are all part of the "measuring and control equipment" industry. Eyepoint Pharmaceuticals vs. Its Competitors Camtek 10x Genomics Allient Aehr Test Systems Transcat Cytek Biosciences Standard BioTools Senseonics Frequency Electronics Quantum-Si Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Camtek (NASDAQ:CAMT) are both measuring and control equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends. Is EYPT or CAMT more profitable? Camtek has a net margin of 28.36% compared to Eyepoint Pharmaceuticals' net margin of -337.93%. Camtek's return on equity of 23.95% beat Eyepoint Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eyepoint Pharmaceuticals-337.93% -63.80% -50.72% Camtek 28.36%23.95%14.98% Do analysts rate EYPT or CAMT? Eyepoint Pharmaceuticals currently has a consensus target price of $26.86, indicating a potential upside of 100.28%. Camtek has a consensus target price of $96.10, indicating a potential upside of 9.64%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Camtek.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eyepoint Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Camtek 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.73 Does the media prefer EYPT or CAMT? In the previous week, Camtek had 8 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 12 mentions for Camtek and 4 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 1.16 beat Camtek's score of 0.86 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Camtek 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, EYPT or CAMT? Eyepoint Pharmaceuticals has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500. Comparatively, Camtek has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500. Do insiders and institutionals have more ownership in EYPT or CAMT? 99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 41.9% of Camtek shares are held by institutional investors. 4.5% of Eyepoint Pharmaceuticals shares are held by insiders. Comparatively, 79.4% of Camtek shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has preferable valuation & earnings, EYPT or CAMT? Camtek has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Camtek, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEyepoint Pharmaceuticals$43.27M21.36-$130.87M-$2.68-5.00Camtek$429.23M9.31$118.51M$2.7332.11 SummaryCamtek beats Eyepoint Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Eyepoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EYPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EYPT vs. The Competition Export to ExcelMetricEyepoint PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$920.18M$3.15B$5.78B$10.19BDividend YieldN/A2.33%5.73%4.61%P/E Ratio-5.0021.2474.8626.40Price / Sales21.36456.43540.53124.73Price / CashN/A44.4425.8129.91Price / Book2.729.6413.256.28Net Income-$130.87M-$53.20M$3.29B$270.38M7 Day Performance-1.76%0.44%0.47%2.70%1 Month Performance20.92%4.26%4.60%5.99%1 Year Performance47.36%9.43%73.42%25.94% Eyepoint Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EYPTEyepoint Pharmaceuticals1.9214 of 5 stars$13.41+0.4%$26.86+100.3%+46.7%$920.18M$43.27M-5.00120Positive NewsCAMTCamtek3.4615 of 5 stars$81.07+2.9%$96.10+18.5%+7.3%$3.59B$429.23M29.70400Positive NewsTXG10x Genomics3.493 of 5 stars$13.93-0.2%$13.54-2.8%-43.5%$1.74B$610.78M-19.901,240Analyst DowngradeALNTAllient2.8222 of 5 stars$45.76+0.5%$35.00-23.5%+124.9%$771.77M$529.97M53.212,525News CoveragePositive NewsAEHRAehr Test Systems2.3449 of 5 stars$25.19-1.4%N/A+104.6%$764.63M$58.97M-193.7590Positive NewsTRNSTranscat3.7979 of 5 stars$79.71+2.0%$112.20+40.8%-39.3%$728.57M$278.42M55.741,245News CoveragePositive NewsShort Interest ↑CTKBCytek Biosciences2.0473 of 5 stars$4.10+2.0%$5.60+36.6%-19.8%$511.44M$200.45M-82.00500Positive NewsLABStandard BioTools2.8287 of 5 stars$1.36+4.6%$1.55+14.0%-37.4%$496.59M$174.43M-4.25620Positive NewsHigh Trading VolumeSENSSenseonics1.7968 of 5 stars$0.44-3.0%$1.54+246.6%+13.0%$361.39M$25.47M-3.4190Gap UpFEIMFrequency Electronics1.4928 of 5 stars$32.64+3.3%N/A+114.3%$308.08M$69.81M13.21200News CoverageEarnings ReportAnalyst UpgradeGap UpQSIQuantum-Si2.7421 of 5 stars$1.06-1.9%$3.48+227.8%+27.8%$218.70M$3.06M-1.56150News CoveragePositive News Related Companies and Tools Related Companies CAMT Alternatives TXG Alternatives ALNT Alternatives AEHR Alternatives TRNS Alternatives CTKB Alternatives LAB Alternatives SENS Alternatives FEIM Alternatives QSI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EYPT) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyepoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyepoint Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
